EValuation of prognostIc and Cost reDuction by tElemonitoring iN CIEDs Usual carE: an Updated Analysis Using 2019-2023 Data
Condition(s) studied
Investigational drug(s) / intervention(s)
No RM exposure: Person-time contributed before RM initiation, or throughout follow-up for patients who never initiated RM
RM exposure: Person-time contributed after RM initiation, or throughout follow-up for patients already receiving RM at cohort entry
Conventional RM: Patients followed remotely through manufacturer-specific platforms
Implicity RM: Patients followed through the universal Implicity platform
Study summary
The EVIDENCE-RM study is a nationwide, non-interventional retrospective study evaluating the clinical and medico-economic impact of remote monitoring (RM) in patients with an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D). Using data from the French national health database (SNDS) between 2019 and 2023, the study compares clinical outcomes and healthcare costs between patients with and without RM, as well as between those monitored via the universal Implicity platform versus conventional manufacturer-specific solutions.
Eligibility
Primary outcome measure(s)
- All-cause mortality — Up to 5 years
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Implicity | Paris | France |
More Implicity trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07881250 on ClinicalTrials.gov ↗ ← All trials in France